|
1
|
Fujiwara Y and Arakawa T: Epidemiology and
clinical characteristics of GERD in the Japanese population. J
Gastroenterol. 44:518–534. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dimenas E: Methodological aspects of
evaluation of quality of life in upper gastrointestinal diseases.
Scand J Gastroenterol Suppl. 199:181993. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meineche-Schmidt V, Talley NJ, Pap A,
Kordecki H, Schmid V, Ohlsson L, Wahlqvist P, Wiklund I and
Bolling-Sternevald E: Impact of functional dyspepsia on quality of
life and health care consumption after cessation of antisecretory
treatment. A multicentre 3-month follow-up study. Scand J
Gastroenterol. 34:566–574. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chiba N, De Gara CJ, Wilkinson JM and Hunt
RH: Speed of healing and symptom relief in grade II to IV
gastroesophageal reflux disease: A meta-analysis. Gastroenterology.
112:1798–1810. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Talley NJ, Meineche-Schmidt V, Paré P,
Duckworth M, Räisänen P, Pap A, Kordecki H and Schmid V: Efficacy
of omeprazole in functional dyspepsia: Double-blind, randomized,
placebo-controlled trials (the Bond and Opera studies). Aliment
Pharmacol Ther. 12:1055–1065. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chey WD, Mody RR and Izat E: Patient and
physician satisfaction with proton pump inhibitors (PPIs): Are
there opportunities for improvement? Dig Dis Sci. 55:3415–3422.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hori Y, Imanishi A, Matsukawa J, et al: 1-
[5- (2- Fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3-
yl]- N- methylmethanamine monofumarate (TAK- 438), a novel and
potent potassium- competitive acid blocker for the treatment of
acid- related diseases. J Pharmacol Exp Ther. 335:231–238. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ashida K, Sakurai Y, Nishimura A, Kudou K,
Hiramatsu N, Umegaki E, Iwakiri K and Chiba T: Randomised clinical
trial: A dose-ranging study of vonoprazan, a novel
potassium-competitive acid blocker, vs. lansoprazole for the
treatment of erosive oesophagitis. Aliment Pharmacol Ther.
42:685–695. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van Zanten SJ Veldhuyzen, Chiba N,
Armstrong D, Barkun AN, Thomson AB, Mann V, Escobedo S, Chakraborty
B and Nevin K: Validation of a 7-point global overall symptom scale
to measure the severity of dyspepsia symptoms in clinical trials.
Aliment Pharmacol Ther. 23:521–529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sakurai K, Nagahara A, Inoue K, Akiyama J,
Mabe K, Suzuki J, Habu Y, Araki A, Suzuki T, Satoh K, et al:
Efficacy of omeprazole, famotidine, mosapride and teprenone in
patients with upper gastrointestinal symptoms: an
omeprazole-controlled randomized study (J-FOCUS). BMC
Gastroenterol. 12:422012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Zanten SV, Armstrong D, Chiba N, Flook
N, White RJ, Chakraborty B and Gasco A: Esomeprazole 40 mg once a
day in patients with functional dyspepsia: The randomized,
placebo-controlled ‘ENTER’ trial. Am J Gastroenterol.
101:2096–2106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Savarino V, Vigneri S and Celle G: The 13C
urea breath test in the diagnosis of Helicobacter pylori infection.
Gut. 45:(Suppl 1). I18–I22. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kimura K and Takemoto T: An endoscopic
recognition of the atrophic border and its significance in chronic
gastritis. Endoscopy. 3:87–97. 1969. View Article : Google Scholar
|
|
14
|
Armstrong D, Bennett JR, Blum AL, Dent J,
De Dombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE,
Spechler SJ, et al: The endoscopic assessment of esophagitis: A
progress report on observer agreement. Gastroenterology. 111:85–92.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soga T, Matsuura M, Kodama Y, Fujita T,
Sekimoto I, Nishimura K, Yoshida S, Kutsumi H and Fujimoto S: Is a
proton pump inhibitor necessary for the treatment of lower-grade
reflux esophagitis? J Gastroenterol. 34:435–440. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Serag H, Becher A and Jones R:
Systematic review: Persistent reflux symptoms on proton pump
inhibitor therapy in primary care and community studies. Aliment
Pharmacol Ther. 32:720–737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fennerty MB and Johnson DA: Heartburn
severity does not predict disease severity in patients with erosive
esophagitis. MedGenMed. 8:62006.PubMed/NCBI
|
|
18
|
Pace F, Negrini C, Wiklund I, Rossi C and
Savarino V: ITALIAN ONE INVESTIGATORS STUDY GROUP: Quality of life
in acute and maintenance treatment of non-erosive and mild erosive
gastro-oesophageal reflux disease. Aliment Pharmacol Ther.
22:349–356. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagahara A, Suzuki T, Nagata N, Sugai N,
Takeuchi Y, Sakurai K, Miyamoto M, Inoue K, Akiyama J, Mabe K, et
al: A multicentre randomised trial to compare the efficacy of
omeprazole versus rabeprazole in early symptom relief in patients
with reflux esophagitis. J Gastroenterol. 49:1536–1547. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fass R: Erosive esophagitis and nonerosive
reflux disease (NERD): Comparison of epidemiologic, physiologic,
and therapeutic characteristics. J Clin Gastroenterol. 41:131–137.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagahara A, Miwa H, Minoo T, Hojo M,
Kawabe M, Osada T, Kurosawa A, Asaoka D, Terai T, Ohkusa T, et al:
Increased esophageal sensitivity to acid and saline in patients
with nonerosive gastro-esophageal reflux disease. J Clin
Gastroenterol. 40:891–895. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adachi K, Katsube T, Kawamura A, Takashima
T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M and Kinoshita
Y: CYP2C19 genotype status and intragastric pH during dosing with
lansoprazole or rabeprazole. Aliment Pharmacol Ther. 14:1259–1266.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shin JM, Inatomi N, Munson K, Strugatsky
D, Tokhtaeva E, Vagin O and Sachs G: Characterization of a novel
potassium-competitive acid blocker of the gastric H, K-ATPase,
1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine
monofumarate (TAK-438). J Pharmacol Exp Ther. 339:412–420. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hori Y, Matsukawa J, Takeuchi T, Nishida
H, Kajino M and Inatomi N: A study comparing the antisecretory
effect of TAK-438, a novel potassium-competitive acid blocker, with
lansoprazole in animals. J Pharmacol Exp Ther. 337:797–804. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tack J, Piessevaux H, Coulie B, Caenepeel
P and Janssens J: Role of impaired gastric accommodation to a meal
in functional dyspepsia. Gastroenterology. 115:1346–1352. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Talley NJ, Tack J, Ptak T, Gupta R and
Giguère M: Itopride in functional dyspepsia: Results of two phase
III multicentre, randomised, double-blind, placebo-controlled
trials. Gut. 57:740–746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iwakiri R, Tominaga K, Furuta K, Inamori
M, Furuta T, Masuyama H, Kanke K, Nagahara A, Haruma K, Kinoshita
Y, et al: Randomised clinical trial: Rabeprazole improves symptoms
in patients with functional dyspepsia in Japan. Aliment Pharmacol
Ther. 38:729–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matsueda K, Hongo M, Tack J, Saito Y and
Kato H: A placebo-controlled trial of acotiamide for meal-related
symptoms of functional dyspepsia. Gut. 61:821–828. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drossman DA: The functional
gastrointestinal disorders and the Rome III process.
Gastroenterology. 130:1377–1390. 2006. View Article : Google Scholar : PubMed/NCBI
|
